Vertex Pharmaceuticals (VRTX) Other Non Operating Income (2012 - 2025)
Vertex Pharmaceuticals' quarterly Other Non Operating Income came in at $6.5 million in Q4 2025, up 143.62% year-on-year from $2.7 million in Q4 2024, and up 166.33% quarter-over-quarter from -$9.8 million in Q3 2025.
Vertex Pharmaceuticals has reported Other Non Operating Income for 14 years, with the latest figure at $6.5 million in Q4 2025.
- For the quarter ending Q4 2025, Other Non Operating Income rose 143.62% year-over-year to $6.5 million; the trailing twelve-month figure through Mar 2026 stood at $9.9 million (up 113.66% YoY), and the FY2025 full-year result was -$7.7 million, up 91.06% from the prior year.
- Other Non Operating Income for Q4 2025 stood at $6.5 million, up from -$9.8 million in the prior quarter.
- The five-year high for Other Non Operating Income was $42.4 million in Q3 2021, with the low at -$78.1 million in Q2 2022.
- Average Other Non Operating Income over 5 years is -$13.8 million, with a median of -$12.4 million recorded in 2023.
- Year-over-year, Other Non Operating Income plunged 2500.0% in 2024 and jumped 157.14% in 2025.
- Tracing VRTX's Other Non Operating Income over 5 years: stood at $7.1 million in 2021, then plunged by 538.03% to -$31.1 million in 2022, then soared by 68.49% to -$9.8 million in 2023, then tumbled by 52.04% to -$14.9 million in 2024, then soared by 143.62% to $6.5 million in 2025.
- The last three Other Non Operating Income figures came in at $6.5 million (Q4 2025), -$9.8 million (Q3 2025), and $13.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.50 Mn |
| Sep 30, 2025 | -9.80 Mn |
| Jun 30, 2025 | 13.20 Mn |
| Mar 31, 2025 | -17.60 Mn |
| Dec 31, 2024 | -14.90 Mn |
| Sep 30, 2024 | -16.90 Mn |
| Jun 30, 2024 | -23.10 Mn |
| Mar 31, 2024 | -31.20 Mn |
| Dec 31, 2023 | -9.80 Mn |
| Sep 30, 2023 | -15.90 Mn |
| Jun 30, 2023 | 1.60 Mn |
| Mar 31, 2023 | 1.30 Mn |
| Dec 31, 2022 | -31.10 Mn |
| Sep 30, 2022 | 17.20 Mn |
| Jun 30, 2022 | -78.10 Mn |
| Mar 31, 2022 | -72.80 Mn |
| Dec 31, 2021 | 7.10 Mn |
| Sep 30, 2021 | 42.40 Mn |
| Jun 30, 2021 | 8.10 Mn |
| Mar 31, 2021 | -52.70 Mn |
| Dec 31, 2020 | 156.80 Mn |
| Sep 30, 2020 | 84.39 Mn |
| Jun 30, 2020 | 116.37 Mn |
| Mar 31, 2020 | -61.13 Mn |
| Dec 31, 2019 | 127.38 Mn |
| Sep 30, 2019 | -31.75 Mn |
| Jun 30, 2019 | 53.94 Mn |
| Mar 31, 2019 | 42.61 Mn |
| Dec 31, 2018 | -90.45 Mn |
| Sep 30, 2018 | -61.00 Mn |
| Jun 30, 2018 | 53.82 Mn |
| Mar 31, 2018 | 96.84 Mn |
| Dec 31, 2017 | -748,000.00 |
| Sep 30, 2017 | -77.55 Mn |
| Jun 30, 2017 | -2.54 Mn |
| Mar 31, 2017 | -544,000.00 |
| Dec 31, 2016 | 1.11 Mn |
| Sep 30, 2016 | -167,000.00 |
| Jun 30, 2016 | -1.22 Mn |
| Mar 31, 2016 | 4.41 Mn |
| Dec 31, 2015 | -1.69 Mn |
| Sep 30, 2015 | -1.33 Mn |
| Jun 30, 2015 | 1.41 Mn |
| Mar 31, 2015 | -5.11 Mn |
| Dec 31, 2014 | -3.79 Mn |
| Sep 30, 2014 | -3.99 Mn |
| Jun 30, 2014 | 36.70 Mn |
| Mar 31, 2014 | 451,000.00 |
| Dec 31, 2013 | 3.34 Mn |
| Sep 30, 2013 | 4.76 Mn |
| Jun 30, 2013 | -34,000.00 |
| Mar 31, 2013 | -1.18 Mn |
| Dec 31, 2012 | 11.73 Mn |
| Sep 30, 2012 | -4.04 Mn |
| Jun 30, 2012 | -3.64 Mn |
| Mar 31, 2012 | -3.74 Mn |